

International conference on

CANNABIS AND MEDICINAL RESEARCH

November 15-16, 2018 Osaka, Japan

Precision dosing: The known and unknowns

Jeremy Riggle^{1,2}¹Mary's Medicinals, USA²Mary's Nutritionals, USA

As the therapeutic potential of cannabinoids for human health become more established and cannabinoid therapy gains broader acceptance as a legitimate form of treatment many new questions emerge. Which cannabinoid is best suited for what specific indication? What is the most efficient route of administration? What is the most effective dose? All of these questions address important details that need to be resolved for appropriate application of cannabinoid therapy to become a reality. In addition, there remain a number of fundamental questions to be answered with regard to the pharmacokinetics and pharmacodynamics of cannabinoids as well as their overall receptor pharmacology including the varying bio-availabilities of different routes of administration, the effects of different dosing regimens, the substantial inter-individual variability, the fluid and constantly changing governmental regulations and significant dearth of high level clinical studies.

Biography

Jeremy Riggle has received his PhD in Analytical Chemistry from the University of Idaho in Moscow, after being awarded MS in Environmental Chemistry also from the University of Idaho and a BS in Biology from Eastern Oregon University in La Grande, USA. He has then worked in the Division of Atmospheric Sciences at Desert Research Institute in Reno, NV, where he focused on the characterization and source apportionment of carbonaceous particulate matter. Following his time at DRI, he worked in the Food Safety and Environmental Stewardship Laboratory at Oregon State University in Corvallis, a toxicology lab where he concentrated on the environmental fate of polynuclear aromatic hydrocarbons. He was an Associate Professor of Chemistry in the Department of Chemistry & Biochemistry at his alma mater, Eastern Oregon University. Shortly after arriving at EOU, he co-founded EOA, a cannabis research and quality control laboratory and, prior to joining Mary's, spent the past several years focusing on the analytics of cannabis, its associated compounds and various cannabinoid formulations.

jeremy@marysmedicinals.com

Notes: